Skip to Content

Movement Disorders

Cervical dystonia

Cervical dystonia is a painful condition in which neck muscles contract involuntarily causing abnormal postures or twisting of the head and neck.

Botulinum toxin therapy is considered standard of care for the symptomatic treatment of cervical dystonia. Other treatment options may include physical therapy or surgery.

In November 2019, Revance completed patient enrollment of the pivotal ASPEN-1 Phase 3 clinical trial evaluating DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia. Topline results are expected in the second half of 2020.

DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA.

30 to 50

Most common age range of onset for cervical dystonia, but the condition can affect younger or older people.1

$200M

Estimated global market opportunity for cervical dystonia.2

Upper Limb Spasticity

Upper limb spasticity is a neurological condition that affects movement in the arms and/or hands and occurs most commonly after a stroke or traumatic brain injury. The condition is associated with muscle stiffness, spasms, and inability to perform daily tasks.

Neurotoxin treatment is the standard of care for management of focal upper limb spasticity. Other treatment options include muscle relaxers and antispastic agents, physical therapy, splints, casts, braces, electrical stimulation, or surgery.

The JUNIPER Phase 2 trial evaluating DaxibotulinumtoxinA for Injection for treatment of adult upper limb spasticity is currently underway.

DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA.

12M

Estimated number of people worldwide who suffer from spasticity.3

<20%

Estimated portion of patient population currently receiving treatment.4

500,000

Estimated number of people in the U.S. who suffer from upper limb spasticity.5

References

  1. Dystonia Society. Neck Dystonia. Available at: https://www.dystonia.org.uk/neck-dystonia. Accessed April 1, 2020.
  2. Based on 2018 estimates from Global Industry Analysts, Inc. Botulinum Toxin – A Global Strategic Business Report, January 2018; DRG Therapeutic Botulinum Toxin Market Analysis Global 2019; UBS Specialty Pharmaceuticals Handbook April 2018; Allergan 2018 Financials, and https://heelthatpain.com/15-plantar-fasciitis-facts/
  3. American Association of Neurological Surgeons. Available at: https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Spasticity. Accessed August 2019.
  4. Munin M et al. Methodology of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging, 36-Week, Multicenter Trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity in Adults After Stroke or Traumatic Brain Injury (JUNIPER). Poster presented at 2019 TOXINS. 16-19 January, 2019. Copenhagen, Denmark.
  5. Medscape. Available at: https://emedicine.medscape.com/article/2207448-overview#showall. Accessed 27 August 2019.
Back to top